See more : Pharos Energy plc (SOCLF) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang East Asia Pharmaceutical Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Risun Group Limited (1907.HK) Income Statement Analysis – Financial Results
- Zosano Pharma Corporation (ZSAN) Income Statement Analysis – Financial Results
- Hoshizaki Corporation (HSHIF) Income Statement Analysis – Financial Results
- Datable Technology Corporation (DAC.V) Income Statement Analysis – Financial Results
- First Niles Financial, Inc. PFD SER A (FNFPA) Income Statement Analysis – Financial Results
Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS)
About Zhejiang East Asia Pharmaceutical Co., Ltd.
Zhejiang East Asia Pharmaceutical Co., Ltd. engages in the manufacture and distribution of active pharmaceutical ingredients (API), tablets, granules and capsules. The company was founded in 1992 and is headquartered in Taizhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.36B | 1.18B | 712.22M | 881.67M | 988.09M | 856.81M | 728.89M | 684.47M |
| Cost of Revenue | 1.01B | 910.40M | 511.16M | 582.18M | 642.29M | 573.61M | 508.49M | 458.05M |
| Gross Profit | 348.75M | 269.15M | 201.05M | 299.49M | 345.80M | 283.21M | 220.40M | 226.42M |
| Gross Profit Ratio | 25.71% | 22.82% | 28.23% | 33.97% | 35.00% | 33.05% | 30.24% | 33.08% |
| Research & Development | 81.74M | 44.95M | 37.29M | 38.41M | 37.19M | 32.70M | 31.05M | 27.01M |
| General & Administrative | 51.11M | 41.27M | 43.97M | 64.13M | 44.69M | 33.75M | 36.64M | 79.31M |
| Selling & Marketing | 13.83M | 9.61M | 9.91M | 9.80M | 13.36M | 12.35M | 8.90M | 8.63M |
| SG&A | 64.93M | 50.88M | 53.88M | 73.94M | 58.05M | 46.11M | 45.54M | 87.93M |
| Other Expenses | 65.11M | 72.98M | 52.18M | 52.31M | 48.45M | -4.42M | 1.19M | 1.65M |
| Operating Expenses | 211.78M | 168.80M | 143.35M | 164.66M | 143.70M | 136.05M | 128.81M | 121.89M |
| Cost & Expenses | 1.22B | 1.08B | 654.51M | 746.84M | 785.99M | 709.65M | 637.30M | 579.94M |
| Interest Income | 11.23M | 13.42M | 21.55M | 4.43M | 2.14M | 727.96K | 506.38K | 471.40K |
| Interest Expense | 4.12M | 842.78K | 218.79K | 656.92K | 3.34M | 7.53M | 16.90M | 18.02M |
| Depreciation & Amortization | 114.38M | 95.67M | 70.45M | 63.60M | 60.80M | 57.75M | 57.01M | 52.08M |
| EBITDA | 253.19M | 210.19M | 148.28M | 193.82M | 258.49M | 193.44M | 142.50M | 149.32M |
| EBITDA Ratio | 18.67% | 17.98% | 21.50% | 22.24% | 26.57% | 23.38% | 20.22% | 23.21% |
| Operating Income | 136.97M | 120.59M | 78.92M | 133.77M | 197.15M | 132.95M | 67.98M | 79.43M |
| Operating Income Ratio | 10.10% | 10.22% | 11.08% | 15.17% | 19.95% | 15.52% | 9.33% | 11.61% |
| Total Other Income/Expenses | -2.28M | -5.50M | -1.86M | -3.58M | -2.80M | -4.42M | 1.19M | 1.65M |
| Income Before Tax | 134.69M | 115.09M | 77.06M | 130.19M | 194.35M | 128.53M | 69.17M | 81.08M |
| Income Before Tax Ratio | 9.93% | 9.76% | 10.82% | 14.77% | 19.67% | 15.00% | 9.49% | 11.85% |
| Income Tax Expense | 13.44M | 10.67M | 8.57M | 15.71M | 26.02M | 19.19M | 13.43M | 14.33M |
| Net Income | 121.25M | 104.43M | 68.49M | 114.48M | 168.33M | 109.34M | 55.74M | 66.75M |
| Net Income Ratio | 8.94% | 8.85% | 9.62% | 12.98% | 17.04% | 12.76% | 7.65% | 9.75% |
| EPS | 1.08 | 0.92 | 0.60 | 1.01 | 1.48 | 1.28 | 0.71 | 0.89 |
| EPS Diluted | 0.97 | 0.92 | 0.60 | 1.01 | 1.48 | 1.28 | 0.71 | 0.89 |
| Weighted Avg Shares Out | 112.58M | 113.60M | 113.60M | 113.60M | 113.60M | 85.42M | 78.51M | 75.00M |
| Weighted Avg Shares Out (Dil) | 125.00M | 113.60M | 113.60M | 113.60M | 113.60M | 85.42M | 78.51M | 75.00M |
No news found for: 605177.SS
Source: https://incomestatements.info
Category: Stock Reports